Welcome to our dedicated page for Silk Road Medical news (Ticker: SILK), a resource for investors and traders seeking the latest updates and insights on Silk Road Medical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Silk Road Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Silk Road Medical's position in the market.
Silk Road Medical (SILK) reported strong financial results for Q4 and the full year 2021, achieving a record revenue of $101.5 million, up 35% from 2020. Q4 revenue reached $28.3 million, a 34% increase year-over-year. Gross profit for the year was $76.0 million, with a gross margin improving to 74.9%. Operating expenses rose to $123.5 million, leading to a net loss of $49.8 million. For 2022, the company projects revenue between $126 million and $132 million.
Silk Road Medical (NASDAQ: SILK) announced it will report its fourth quarter and full year 2021 financial results after market close on February 24, 2022. A conference call will follow at 1:30 PM PT / 4:30 PM ET. Investors can join the call by dialing (844) 883-3861 or (574) 990-9820 for international callers, using conference ID: 2046067. This session will provide insights into the company's strategies and financial performance in stroke risk reduction through its innovative TransCarotid Artery Revascularization (TCAR) procedure.
Silk Road Medical (Nasdaq: SILK) will participate in the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022. The management team is scheduled for a fireside chat at 1:40 p.m. ET. Interested stakeholders can access the live and archived webcast through the Investors section of their website. Silk Road Medical is committed to reducing stroke risks through innovative treatments like TransCarotid Artery Revascularization (TCAR), which merges neuroprotection with minimally invasive techniques.
Silk Road Medical (NASDAQ: SILK) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2022, at 3:45 p.m. ET. The presentation will focus on the company’s innovative approach to reducing stroke risk, specifically through its TransCarotid Artery Revascularization (TCAR) procedure. Interested parties can access the live and archived webcast via the company’s Investors section on its website. The company aims to improve patient outcomes through advanced clinical techniques.
Silk Road Medical (Nasdaq: SILK) announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 10, 2021. The company focuses on reducing stroke risk through its innovative TransCarotid Artery Revascularization (TCAR) procedure. A recording of the presentation will be available online starting November 22, 2021, at 10:00 a.m. Eastern Time. Interested parties can access it through the company’s website. Silk Road Medical is dedicated to improving patient outcomes by addressing carotid artery disease.
Silk Road Medical reported a 23% revenue increase for Q3 2021, totaling $24.7 million, compared to $20.1 million in Q3 2020. Gross profit also rose to $18.6 million with a gross margin of 75%. However, operating expenses surged by 33% to $31.9 million, leading to a net loss of $13.9 million or $0.40 per share. The company now projects full-year revenue between $99 million and $102 million, reflecting an anticipated growth of 32% to 36% despite challenges posed by the COVID-19 delta variant.
Silk Road Medical, a leader in stroke risk reduction technologies, will participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 1:20 p.m. ET. The event will feature a fireside chat showcasing the company’s pioneering TransCarotid Artery Revascularization (TCAR) procedure, which combines surgical principles and minimally invasive techniques to treat carotid artery disease. Interested parties can access the live and archived webcast via the company’s website.
For more information, visit www.silkroadmed.com.
Silk Road Medical, Inc. (NASDAQ: SILK), focused on reducing stroke risk, will report its third quarter 2021 financial results on November 9, 2021, after market close. A conference call for investors will follow at 1:30 p.m. PT (4:30 p.m. ET). Interested listeners can join by dialing (844) 883-3861 domestically or (574) 990-9820 internationally, using conference ID: 3998078. Silk Road Medical is pioneering TransCarotid Artery Revascularization (TCAR) for carotid artery disease treatment, combining surgical neuroprotection with minimally invasive techniques.
Silk Road Medical (Nasdaq: SILK) will participate in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at 2:00 p.m. Eastern Time. The event will focus on the company's innovative approach to reducing stroke risk through its TransCarotid Artery Revascularization (TCAR) procedure. Interested parties can access a live and archived webcast via the company’s Investors section online. For more details, visit their website.
Silk Road Medical (NASDAQ: SILK) announced positive findings from a large-scale analysis on Transcarotid Artery Revascularization (TCAR) presented at the Society for Vascular Surgery 2021 Vascular Annual Meeting. The study involved over 20,000 patients, revealing that TCAR achieved similar stroke and death rates compared to carotid endarterectomy (CEA), but with a significant ninefold reduction in cranial nerve injury (CNI) incidents (0.3% vs 2.7%, p=<0.001). These results highlight the effectiveness of TCAR as a less invasive treatment option for carotid artery disease.
FAQ
What is the current stock price of Silk Road Medical (SILK)?
What is the market cap of Silk Road Medical (SILK)?
